https://scholars.lib.ntu.edu.tw/handle/123456789/584458
標題: | Prognostic value of CD1B in localised prostate cancer | 作者: | Lee C.-H. Chen L.-C. Yu C.-C. Lin W.-H. Lin V.C. CHAO-YUAN HUANG Lu T.-L. Huang S.-P. Bao B.-Y. |
關鍵字: | Biomarker; CD antigen; CD1B; Prognosis; Prostate cancer | 公開日期: | 2019 | 出版社: | MDPI AG | 卷: | 16 | 期: | 23 | 起(迄)頁: | 4723 | 來源出版物: | International Journal of Environmental Research and Public Health | 摘要: | Cluster of differentiation (CD) antigens are cell surface markers used to differentiate haematopoietic cell types. These antigens are present in various malignancies and are reportedly linked to patient prognosis; however, they have not been implemented as prostate cancer progression markers. Here, we aimed to assess the impact of genetic variation in haematopoietic cell CD markers on clinical outcomes in patients with prostate cancer. An association study of 458 patients with prostate cancer was conducted to identify single-nucleotide polymorphisms in 11 candidate CD marker genes associated with biochemical recurrence (BCR) after radical prostatectomy. Identified predictors were further evaluated in an additional cohort of 185 patients. Joint population analyses showed that CD1B rs3181082 is associated with BCR (adjusted hazard ratio 1.42, 95% confidence interval 1.09-1.85, p = 0.010). In addition, rs3181082 overlapped with predicted transcriptional regulatory elements and affected CD1B expression. Furthermore, low CD1B expression correlated with poorer BCR-free survival. Our results indicated that CD1B rs3181082 confers prostate cancer progression and may help improve clinical prognostic stratification. ? 2019 by the authors. Licensee MDPI, Basel, Switzerland. |
URI: | https://www.scopus.com/inward/record.uri?eid=2-s2.0-85075790718&doi=10.3390%2fijerph16234723&partnerID=40&md5=e5d7d062e257ff9e585114cd6fddedb5 https://scholars.lib.ntu.edu.tw/handle/123456789/584458 |
ISSN: | 1661-7827 | DOI: | 10.3390/ijerph16234723 | SDG/關鍵字: | CD1b antigen; cell marker; CD1 antigen; CD1b antigen; tumor marker; antigen; biomarker; cancer; cell; confidence interval; gene expression; prediction; Article; biochemical recurrence free survival; cancer growth; cancer localization; cancer prognosis; CD1B gene; clinical assessment; clinical outcome; cohort analysis; gene expression; genetic association; genetic association study; genetic correlation; genetic variability; genetic variation; genotype; hazard ratio; hematopoietic cell; human; human cell; human tissue; major clinical study; male; overall survival; prostate cancer; prostatectomy; single nucleotide polymorphism; transcription regulation; aged; genetics; metabolism; middle aged; predictive value; proportional hazards model; prostate tumor; Aged; Antigens, CD1; Biomarkers, Tumor; Humans; Male; Middle Aged; Polymorphism, Single Nucleotide; Predictive Value of Tests; Proportional Hazards Models; Prostatic Neoplasms |
顯示於: | 醫學系 |
在 IR 系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。